Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Croda International Plc (50GP.L)
Goole, GB
Croda International Plc is a global enterprise specializing in the development, manufacturing, and distribution of high-performance chemicals, with its market reach spanning Europe, the Middle East, Africa, North America, Asia, and Latin America. The company's operations are strategically organized across four main divisions: Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. Croda's diverse product portfolio caters to numerous sectors. For agriculture, it provides solutions such as crop protection enhancers, seed treatment technologies, animal health compounds, bio-stimulants, and specialized additives for farming films. The industrial landscape benefits from its range of adhesives, lubricant components, protective coatings, polymer solutions, vehicle maintenance chemicals, and advanced additives for plastics, batteries, and catalysts, along with materials for automotive textiles and fibers. Within consumer care, Croda supplies essential ingredients for a broad spectrum of personal care applications, including skin, hair, sun, body, and baby care items, as well as components for cosmetics, deodorants, anti-perspirants, depilatories, men's grooming, and oral hygiene products. Its Life Sciences segment is a key supplier of active pharmaceutical ingredients, dietary supplements, and various health-related products. The company's expertise also extends to construction chemicals, bitumen additives, and specialized materials and polymer additives vital for electronics and devices. It offers chemistries, emulsifiers, fuel and power generation additives, and unique polymer additives designed for furniture and wood. Furthermore, Croda contributes to household, industrial, and institutional cleaning products, oleochemicals, and chemicals used in packaging, printing, and paper manufacturing, in addition to paints and coatings. A significant area of Croda's innovation lies in thermal management products and advanced bio-based phase change materials, which are critical for temperature control across varied applications, from buildings and apparel to healthcare, electronics, food refrigeration, energy storage, and automotive systems. Established in 1925, Croda International Plc maintains its headquarters in Goole, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.69% | +7.01% | +6.33% | +1.20% | +10,669.23% | +10,669.23% | +10,669.23% | +1.20% | -18.45% | -14.72% | -8.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%+4.4% Q4'25: +3.7% (vs Q4'23)
-
EPS growth Chemicals - Specialty: +13.2%-61.4% Q4'25: -99.1% (vs Q4'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+11.8% Q4'25: +16.4% (vs Q4'23)
-
EBIT margin Chemicals - Specialty: +8.8%+14.3% ★ Q4'25: +13.6% (vs Q4'23)
-
ROIC Chemicals - Specialty: +5.6%+6.4% ★ Q4'25: +10.1% (vs Q4'23)
-
Share dilution Chemicals - Specialty: +0.1%0.0% Q4'25: +2.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.83× Q4'25: 0.96× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 1 EPS Ana. |
Dec 2027 13 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
Dec 2029 12 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.69B
est: 1.71B (-1.0%)
|
1.63B
est: 1.64B (-0.5%)
|
1.70B
est: 1.68B (+0.9%)
|
1.77B
1.73B – 1.84B
+5.1% YoY
|
1.85B
1.81B – 1.95B
+4.6% YoY
|
1.93B
1.89B – 2.02B
+4.6% YoY
|
2.04B
1.99B – 2.13B
+5.3% YoY
|
2.13B
2.08B – 2.23B
+4.7% YoY
|
| EBITDA |
388.50M
est: 479.18M (-18.9%)
|
374.50M
est: 463.59M (-19.2%)
|
380.70M
est: 477.17M (-20.2%)
|
501.40M
489.17M – 520.52M
+5.1% YoY
|
524.24M
512.50M – 551.75M
+4.6% YoY
|
548.21M
535.40M – 573.13M
+4.6% YoY
|
577.31M
563.82M – 603.56M
+5.3% YoY
|
604.65M
590.52M – 632.14M
+4.7% YoY
|
| EBIT |
262.20M
est: 376.78M (-30.4%)
|
238.70M
est: 347.02M (-31.2%)
|
243.70M
est: 357.18M (-31.8%)
|
375.32M
366.16M – 389.63M
+5.1% YoY
|
392.42M
383.63M – 413.01M
+4.6% YoY
|
410.36M
400.77M – 429.02M
+4.6% YoY
|
432.14M
422.04M – 451.79M
+5.3% YoY
|
452.61M
442.03M – 473.18M
+4.7% YoY
|
| Net Income |
171.00M
est: 223.38M (-23.4%)
|
158.50M
est: 190.25M (-16.7%)
|
62.00M
est: 197.60M (-68.6%)
|
220.13M
213.44M – 233.14M
+11.4% YoY
|
247.81M
240.28M – 262.45M
+12.6% YoY
|
272.95M
264.65M – 289.08M
+10.1% YoY
|
303.97M
294.73M – 321.93M
+11.4% YoY
|
318.38M
308.71M – 337.20M
+4.7% YoY
|
| SGA |
482.50M
est: 229.68M (+110.1%)
|
506.40M
est: 433.61M (+16.8%)
|
349.10M
est: 446.31M (-21.8%)
|
468.97M
457.53M – 486.85M
+5.1% YoY
|
490.34M
479.36M – 516.07M
+4.6% YoY
|
512.75M
500.77M – 536.06M
+4.6% YoY
|
539.97M
527.35M – 564.52M
+5.3% YoY
|
565.54M
552.32M – 591.25M
+4.7% YoY
|
| EPS |
1.22
est: 1.60 (-23.7%)
|
1.14
est: 1.36 (-16.3%)
|
0.44
est: 1.42 (-68.9%)
|
1.58
1.53 – 1.67
+11.4% YoY
|
1.77
1.72 – 1.88
+12.6% YoY
|
1.95
1.90 – 2.07
+10.1% YoY
|
2.18
2.11 – 2.31
+11.4% YoY
|
2.28
2.21 – 2.41
+4.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-06-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Edward Foots | Group Chief Executive & Executive Director | 2M | male |
| Stephen Richard Oxley | Chief Financial Officer & Executive Director | 918.7K | male |
| Michelle Fargen | Global Head of Procurement and Sustainable Sourcing | — | — |
| Michelle Lydon | President of Human Resources | — | female |
| Philip Ruxton | Chief Sustainability Officer | — | male |
| Sandra Elaine Breene | President of Consumer Care | — | female |
| Stephen W. Burgess | Managing Director of Nucleic Acid Delivery | — | — |
| Thiru Selvan | President of Supply Chain Operations | — | male |
| Thomas Michael Brophy | Group General Counsel, Company Secretary & President Sustainability | — | male |
| Anthony Damien Fitzpatrick | President of Strategy, Corporate Development & Industrial Specialties | — | male |
| Thomas Riemeier | President of Life Sciences | — | male |
| David Bishop | Director of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 50GP.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
